6 research outputs found
Anemia experienced by all subjects (months 0–24, all randomized participants).
<p>Data are reported as incidence of participants with at least one episode of anemia per 100 person-years at risk (PYAR) with 95% confidence intervals (incidence per PYAR [95% confidence interval]) among participants given at least one dose of vaccine. Based on 331.2 PYAR for FMP2.1/AS02<sub>A</sub> group and 331.9 PYAR for control group. *P<0.05.</p
Allele-specific vaccine efficacy against <i>P. falciparum</i> malaria, intention-to-treat cohort.
<p>PYAR, Person Years At Risk. CI, confidence interval. ND, not done.</p>*<p>Efficacy was calculated as 1– hazard ratio obtained using Cox proportional hazards modeling.</p>†<p>Rate of malaria episodes per person-year at risk.</p>‡<p>Efficacy was calculated as 1– risk ratio obtained using Poisson regression.</p
Vaccine efficacy against first episode of clinical malaria with apical membrane antigen 1 (AMA1) cluster 1 loop (c1L) identical to the vaccine strain 3D7 during the entire follow-up period (study days 0–730), intention-to-treat.
<p>Vaccine efficacy against first episode of clinical malaria with apical membrane antigen 1 (AMA1) cluster 1 loop (c1L) identical to the vaccine strain 3D7 during the entire follow-up period (study days 0–730), intention-to-treat.</p
Serious adverse events experienced by all subjects (months 0–24, all randomized participants).
<p>Data are reported as: Number of participants with a serious adverse event (% [95% confidence interval]) among participants given at least one dose of vaccine.</p